Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACER Acer Therapeutics	$0.66	$0.74	$0.55 ▼ $4.56	$16.15M	N/A	N/A	574,675 shs
ANRO Alto Neuroscience	$2.35 +2.0%	$2.47	$1.60 ▼ $17.55	$63.48M	1.93	407,258 shs	2.61 million shs
IOBT IO Biotech	$1.44 -2.7%	$1.20	$0.66 ▼ $1.73	$94.87M	0.36	281,573 shs	145,095 shs
MIST Milestone Pharmaceuticals	$1.86 -4.1%	$1.48	$0.63 ▼ $2.75	$99.44M	0.92	946,296 shs	1.09 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACER Acer Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ANRO Alto Neuroscience	0.00%	+5.63%	-10.15%	+8.31%	-78.06%
IOBT IO Biotech	0.00%	+10.77%	+4.35%	+32.11%	+23.08%
MIST Milestone Pharmaceuticals	0.00%	+10.06%	+14.46%	+132.50%	+40.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACER Acer Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	2.6578 of 5 stars	3.3	2.0	0.0	0.0	2.4	0.0	1.3
IOBT IO Biotech	3.2071 of 5 stars	3.7	3.0	0.0	0.0	2.7	2.5	0.6
MIST Milestone Pharmaceuticals	3.0225 of 5 stars	3.2	5.0	0.0	0.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACER Acer Therapeutics	0.00	N/A	N/A	N/A
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	262.47% Upside
IOBT IO Biotech	3.33	Buy	$9.33	548.15% Upside
MIST Milestone Pharmaceuticals	2.40	Hold	$7.00	276.34% Upside

Current Analyst Ratings Breakdown

Latest ACER, IOBT, MIST, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/5/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$5.00
5/15/2025	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/14/2025	IOBT IO Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/7/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
4/1/2025	MIST Milestone Pharmaceuticals	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/1/2025	IOBT IO Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/1/2025	MIST Milestone Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	MIST Milestone Pharmaceuticals	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACER Acer Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$5.62 per share	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	$0.71 per share	N/A
MIST Milestone Pharmaceuticals	$1M	99.44	N/A	N/A	$0.25 per share	7.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACER Acer Therapeutics	-$26.24M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	-$61.43M	-$2.34	N/A	N/A	N/A	N/A	-39.35%	-33.86%	8/12/2025 (Estimated)
IOBT IO Biotech	-$95.49M	-$1.37	N/A	N/A	N/A	N/A	-162.55%	-125.08%	8/12/2025 (Estimated)
MIST Milestone Pharmaceuticals	-$41.52M	-$0.78	N/A	N/A	N/A	N/A	-329.85%	-67.20%	8/6/2025 (Estimated)

Latest ACER, IOBT, MIST, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	MIST Milestone Pharmaceuticals	-$0.19	-$0.31	-$0.12	-$0.31	N/A	N/A
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	-$0.53	+$0.06	-$0.56	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACER Acer Therapeutics	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACER Acer Therapeutics	N/A	N/A	N/A
ANRO Alto Neuroscience	0.15	22.53	22.53
IOBT IO Biotech	N/A	2.32	2.32
MIST Milestone Pharmaceuticals	4.06	4.67	4.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACER Acer Therapeutics	N/A
ANRO Alto Neuroscience	N/A
IOBT IO Biotech	54.76%
MIST Milestone Pharmaceuticals	86.18%

Insider Ownership

Company	Insider Ownership
ACER Acer Therapeutics	20.20%
ANRO Alto Neuroscience	N/A
IOBT IO Biotech	2.30%
MIST Milestone Pharmaceuticals	19.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACER Acer Therapeutics	30	24.46 million	19.52 million	Not Optionable
ANRO Alto Neuroscience	N/A	27.07 million	N/A	N/A
IOBT IO Biotech	30	65.88 million	64.37 million	Not Optionable
MIST Milestone Pharmaceuticals	30	53.46 million	43.04 million	Optionable

ACER, IOBT, MIST, and ANRO Headlines

Recent News About These Companies

Milestone Pharmaceuticals Inc (MIST) - Investing.com

June 29 at 11:33 AM | investing.com

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

June 16, 2025 | finance.yahoo.com

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

June 16, 2025 | globenewswire.com

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages

June 16, 2025 | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Milestone Pharmaceuticals (NASDAQ:MIST)

June 5, 2025 | marketbeat.com

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Sees Large Decrease in Short Interest

June 4, 2025 | marketbeat.com

Toronto Dominion Bank Buys New Stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

June 1, 2025 | marketbeat.com

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

May 22, 2025 | zacks.com

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

May 15, 2025 | finanznachrichten.de

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

May 14, 2025 | globenewswire.com

Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT

April 9, 2025 | seekingalpha.com

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst

April 2, 2025 | zacks.com

Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright

April 2, 2025 | markets.businessinsider.com

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

April 2, 2025 | finance.yahoo.com

Milestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD Cowen

April 2, 2025 | markets.businessinsider.com

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

March 29, 2025 | marketwatch.com

Milestone Stock Crashes After Surprise Tachycardia Drug Rejection

March 29, 2025 | biospace.comB

Milestone Pharmaceuticals Inc.: FDA Issues Complete Response Letter for Etripamil for PSVT

March 28, 2025 | finanznachrichten.de

Milestone stock tumbles after FDA letter on etripamil

March 28, 2025 | ca.investing.com

Manufacturing issues trip up Milestone's long-awaited FDA landmark

March 28, 2025 | fiercepharma.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACER, IOBT, MIST, and ANRO Company Descriptions

Acer Therapeutics NASDAQ:ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Alto Neuroscience NYSE:ANRO

$2.35 +0.05 (+1.96%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$3.20 +0.86 (+36.46%)

As of 04:00 AM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

IO Biotech NASDAQ:IOBT

$1.44 -0.04 (-2.70%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.41 -0.03 (-2.08%)

As of 04:05 AM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Milestone Pharmaceuticals NASDAQ:MIST

$1.86 -0.08 (-4.12%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.86 -0.01 (-0.27%)

As of 04:00 AM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time